Newsroom

比利時根特與東京--(BUSINESS WIRE)--(美國商業資訊)-- H.U. Group Holdings Inc.及其全資子公司Fujirebio今日宣布，巴西衛生監管局(ANVISA)已核准Lumipulse G NfL Blood和Lumipulse G pTau 217 Plasma檢測，供巴西地區的全自動LUMIPULSE® G免疫分析平台使用。 Fujirebio Europe N.V.執行長Christiaan De Wilde表示：「ANVISA核准Lumipulse G NfL Blood和Lumipulse G pTau 217 Plasma檢測，是我們致力於讓全球臨床醫師和患者更容易取得可靠且具有臨床意義的血液生物標記又一項重要進展。透過在單一全自動平台上為實驗室提供這兩項神經生物標記檢測，我們協助在廣泛的神經疾病及整個診斷流程中，支援更完善的臨床決策。」 巴西ANVISA的核准是基於這兩項檢測已取得CE標誌並獲得體外診斷(IVD)核准，反映其符合不同監管機構的安全性和效能要求。本月稍早，這兩項檢測也獲得加拿大衛生部核發的Class II醫療器材許可證(M...

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 9/1/2026 Issue ¦ National Grid Gas plc - Series 46 GBP 25,000,000 Index Linked FRN due 30 Mar 2037     ISIN Number ¦ XS0281936889 ISIN Reference ¦ 28193688 Issue Nomin GBP ¦ 25000000 Period ¦ 9/30/2026 to 3/30/2027   Payment Date 3/30/2027 Number of Days ¦ 181 Rate ¦ 3.75473   Denomination GBP ¦ 50000   ¦ 25000000   ¦       Amount Payable per Denomination ¦ 938.68   ¦ 469341.12   ¦       Bank of New...

SAINT-JEAN-DE-SOUDAIN, France--(BUSINESS WIRE)--Regulatory News: SergeFerrari Group (FR0011950682 - ALFER), l’un des leaders mondiaux dans les toiles composites innovantes, et coté sur Euronext Growth. Publication du nombre d'actions composant le capital et du nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF). Date d’arrêt des informations Nombre total d’actions composant le capital Nombre total de droits de vote 31 août 2026 12 29...

比利时根特与东京--(BUSINESS WIRE)--(美国商业资讯)-- H.U. Group Holdings Inc.及其全资子公司Fujirebio今日宣布，巴西卫生监管局（ANVISA）已批准Lumipulse G NfL血液检测试剂及Lumipulse G pTau 217血浆检测试剂在巴西上市。这两款试剂盒均适用于全自动LUMIPULSE®G免疫检测平台。 Fujirebio Europe N.V.首席执行官Christiaan De Wilde表示，“巴西国家卫生监督局（ANVISA）批准Lumipulse G NfL血液检测试剂和Lumipulse G pTau 217血浆检测试剂，标志着我们在实现‘让全球临床医生和患者更广泛地获取可靠、具临床意义的血液生物标志物’这一使命的道路上又迈出了重要一步。通过在单一全自动平台上为实验室同时提供这两项神经系统生物标志物检测试剂，我们正在助力临床医生针对多种神经系统疾病，在整个诊断流程中做出更明智的决策。” 巴西国家卫生监督局（ANVISA）的授权基于这两项检测试剂已获得的CE认证体外诊断（IVD）批准，这表明其符合各监管机构的...

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 8/28/2026 Issue ¦ National Grid Electricity Transmission - Series 22 GBP 75,000,000 FRN Due 28 Sep 2035     ISIN Number ¦ XS0230845207 ISIN Reference ¦ 23084520 Issue Nomin GBP ¦ 75000000 Period ¦ 9/28/2026 to 3/28/2027   Payment Date 3/30/2027 Number of Days ¦ 181 Rate ¦ 4.515586   Denomination GBP ¦ 50000   ¦ 75000000   ¦       Amount Payable per Denomination ¦ 1128.9   ¦ 1693344.82   ¦       Bank...

GENT, Belgien & TOKIO--(BUSINESS WIRE)--Die H.U. Group Holdings Inc. und ihre hundertprozentige Tochtergesellschaft Fujirebio gaben heute bekannt, dass die brasilianische Gesundheitsaufsichtsbehörde (ANVISA) die Marktzulassung für die Tests „Lumipulse G NfL Blood“ und „Lumipulse G pTau 217 Plasma“ zur Verwendung auf der vollautomatischen LUMIPULSE® G-Immunoassay-Plattform in Brasilien erteilt hat. „Die Zulassung der Tests Lumipulse G NfL Blood und Lumipulse G pTau 217 Plasma durch die ANVISA st...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and...

GENT, België & TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. en zijn dochteronderneming Fujirebio volledig in handen van de holding, maakten vandaag bekend dat ANVISA, de Braziliaanse toezichthoudende gezondheidsinstantie, een handelsvergunning heeft toegekend voor de Lumipulse G NfL Blood en Lumipulse G pTau 217 Plasma-testen voor gebruik op de volledig geautomatiseerde LUMIPULSE® G immunoassay-platform in Brazilië. “De vergunning van ANVISA voor de Lumipulse G NfL Blood en Lumipulse G pTau...

NEW YORK--(BUSINESS WIRE)--Wealth.com, the leading estate and tax planning platform for wealth management firms, today announced it is a launch partner for Claude for Financial Advisors. Estate and tax planning demand a level of precision that few advisor workflows do. Questions about what a trust provides, who holds authority under a health care directive or what the financial impact of a tax strategy would be must be grounded in executed documents, applicable law and validated quantitative an...

NEW YORK--(BUSINESS WIRE)--The Estée Lauder Companies Inc. (NYSE: EL) today announced a global strategic partnership with Profound, the category-defining AI marketing platform, advancing its ambition to be prestige beauty’s leader in AI-native discovery. The partnership will provide the company with visibility into how its full portfolio of brands is represented across leading generative AI platforms, as well as opportunities to optimize that representation. This partnership establishes the com...